Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Hims’ second-quarter revenue fell 7% from a quarter ago. The decline goes beyond weakness in its GLP-1 weight-loss business.

At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more ...

Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The telehealth-consultation platform posted an increase in profit and revenue for the second quarter on growth in subscribers ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

Shares of Hims & Hers Inc. fell after hours on Monday after the wellness and telehealth platform’s third-quarter forecast ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...